A review of coumarin derivatives in pharmacotherapy of breast cancer.
暂无分享,去创建一个
M. Musa | J. Cooperwood | M. O. Khan | John S Cooperwood | M Omar F Khan | Musiliyu A Musa | John S. Cooperwood
[1] J. Mohler,et al. An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin , 2005, Journal of Cancer Research and Clinical Oncology.
[2] S. Mohr,et al. An estradiol-porphyrin conjugate selectively localizes into estrogen receptor-positive breast cancer cells. , 2002, Bioorganic & medicinal chemistry.
[3] K. Gumireddy,et al. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. , 2004, Bioorganic & medicinal chemistry letters.
[4] E. Bickoff,et al. Coumestrol, a new estrogen isolated from forage crops. , 1957, Science.
[5] Atul Purohit,et al. Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. , 2003, Bioorganic & medicinal chemistry letters.
[6] F. Jensen,et al. Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives. , 2008, European journal of medicinal chemistry.
[7] J. Mohler,et al. Phase II evaluation of coumarin (1,2‐benzopyrone) in metastatic prostatic carcinoma , 1992, The Prostate.
[8] V. B. Lohray,et al. Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents. , 2003, Bioorganic & medicinal chemistry letters.
[9] David W. Anderson,et al. Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models. , 2002, Cancer research.
[10] I. Pollard,et al. The oestrogenic and anti-oestrogenic activity of some synthetic steroids and non-steroids. , 1968, Steroids.
[11] M. Hung,et al. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant--taxoid conjugates as novel cytotoxic agents. , 2007, Bioorganic & medicinal chemistry letters.
[12] B. Potter,et al. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. , 2000, Chemistry & biology.
[13] H. J. Woerdenbag,et al. Structure -Cytotoxicity Relationships of a Series of Natural and Semi-Synthetic Simple Coumarins as Assessed in Two Human Tumour Cell Lines , 1997, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[14] B. Halliwell,et al. Interactions of a series of coumarins with reactive oxygen species. Scavenging of superoxide, hypochlorous acid and hydroxyl radicals. , 1992, Biochemical pharmacology.
[15] N. Swamy,et al. Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer. , 1999, Bioorganic & medicinal chemistry letters.
[16] I. Kostova,et al. Synthesis, Characterization, and Cytotoxic Activity of New Lanthanum(III) Complexes of Bis-Coumarins , 2006, Bioinorganic chemistry and applications.
[17] J. Liehr,et al. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. , 2001, Human reproduction update.
[18] M. Dukes,et al. Arimidex®: A potent and selective fourth-generation aromatase inhibitor , 2004, Breast Cancer Research and Treatment.
[19] S. Yoshida,et al. Chemical aspects of coumarin compounds for the prevention of hepatocellular carcinomas. , 2005, Current medicinal chemistry. Anti-cancer agents.
[20] N. Robert,et al. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. , 2005, MedGenMed : Medscape general medicine.
[21] O. Wolf,et al. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans , 1999, Brain Research Reviews.
[22] P. Lønning,et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] S. Milano,et al. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[24] J. Pasqualini,et al. Importance of estrogen sulfates in breast cancer. , 1989, Journal of steroid biochemistry.
[25] David W. Anderson,et al. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF. , 2003, Cytokine.
[26] E Uriarte,et al. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. , 2005, Current medicinal chemistry.
[27] Stewart A. Brown,et al. The natural coumarins : occurrence, chemistry, and biochemistry , 1982 .
[28] A. Chaigneau,et al. In vitro and in vivo models for the evaluation of new inhibitors of human steroid sulfatase, devoid of residual estrogenic activity , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[29] A. Cavalli,et al. Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes. , 1998, Bioorganic & medicinal chemistry.
[30] G. Lukatela,et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. , 1998, Biochemistry.
[31] C. Owen,et al. Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. , 2002, Current medicinal chemistry.
[32] F. Jänicke. Are all aromatase inhibitors the same? A review of the current evidence. , 2004, Breast.
[33] A. Børresen-Dale,et al. Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer , 2003, Breast Cancer Research.
[34] R. G. Morgan,et al. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. , 1993, The New England journal of medicine.
[35] Takeshi Usui,et al. Pharmaceutical prospects of phytoestrogens. , 2006, Endocrine journal.
[36] A. Katritzky,et al. Comprehensive heterocyclic chemistry on CD-ROM , 1997 .
[37] M. Degregorio,et al. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[38] N. Wenger,et al. Postmenopausal hormone therapy, SERMs, and coronary heart disease in women , 1999, Journal of endocrinological investigation.
[39] R. Nicholson,et al. Non-steroidal and steroidal sulfamates: new drugs for cancer therapy , 2001, Molecular and Cellular Endocrinology.
[40] T. Owa,et al. Anticancer and antiviral sulfonamides. , 2003, Current medicinal chemistry.
[41] B. Potter,et al. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. , 1996, Cancer research.
[42] T. Dierks,et al. Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A. , 1998, Biochemistry.
[43] B. Haynes,et al. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. , 1990, Biochemical pharmacology.
[44] B. Potter,et al. Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates. , 1996, Journal of medicinal chemistry.
[45] G. Feuer,et al. Inhibition and enhancement of mammary tumorigenesis by 7,12-dimethylbenz (a) anthracene in the female sprague-dawley rat. , 1974, International journal of clinical pharmacology, therapy and toxicology.
[46] B. Potter,et al. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. , 1998, Journal of medicinal chemistry.
[47] Yate-Ching Yuan,et al. Biochemical and Biological Characterization of a Novel Anti-aromatase Coumarin Derivative* , 2004, Journal of Biological Chemistry.
[48] C K Osborne,et al. Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Novel antineoplastic agents with efficacy against multidrug resistant tumor cells. , 1998, Bioorganic & medicinal chemistry letters.
[50] D. McDonnell,et al. The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.
[51] Alan R. Katritzky,et al. Comprehensive Heterocyclic Chemistry IV , 1996 .
[52] J. Rousseau,et al. Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates. , 2007, Bioorganic & medicinal chemistry letters.
[53] G. Mor,et al. The potential of aromatase inhibitors in breast cancer prevention. , 1999, Endocrine-related cancer.
[54] R. Kitz,et al. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.
[55] B. Long,et al. Aromatase inhibitors and their antitumor effects in model systems. , 1999, Endocrine-related cancer.
[56] J R Hoult,et al. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. , 1996, General pharmacology.
[57] M. Castiglione‐Gertsch. New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity. , 1996, European journal of cancer.
[58] B. Potter,et al. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. , 1995, Biochemistry.
[59] T. Dierks,et al. Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis. , 2001, Journal of molecular biology.
[60] B. Potter,et al. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[61] L. Demers. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients , 2004, Breast Cancer Research and Treatment.
[62] T. Dierks,et al. Sulfatases, Trapping of the Sulfated Enzyme Intermediate by Substituting the Active Site Formylglycine * , 1998, The Journal of Biological Chemistry.
[63] B. Potter,et al. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[64] S. Raleva,et al. Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors , 2006, Bioinorganic chemistry and applications.
[65] M. Ellis,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] C. Siegers,et al. Antitumor-activities of coumarin, 7-hydroxy-coumarin and its glucuronide in several human tumor cell lines. , 1998, Research communications in molecular pathology and pharmacology.
[67] D. Fowlkes,et al. Comparative Analyses of Mechanistic Differences Among Antiestrogens1. , 1999, Endocrinology.
[68] G. Contesso,et al. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents , 1994, Cancer.
[69] D. Kingston,et al. Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. , 2004, Journal of natural products.
[70] B. Potter,et al. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. , 2000, Cancer research.
[71] I. Soubeyran,et al. Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. , 1996, British Journal of Cancer.
[72] J. Henley,et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma , 2005, Journal of Cancer Research and Clinical Oncology.
[73] David W. Anderson,et al. Differential Response of Estrogen Receptors α and β to SP500263, a Novel Potent Selective Estrogen Receptor Modulator , 2002 .
[74] W. Yue,et al. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. , 1998, Oncology.
[75] R. Coombes,et al. Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor , 2006, Clinical Cancer Research.
[76] B. Potter,et al. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[77] G. Leclercq,et al. Diethylstilbestrol-linked cytotoxic agents: synthesis and binding affinity for estrogen receptors. , 1989, Journal of medicinal chemistry.
[78] Yate-Ching Yuan,et al. What do we know about the mechanisms of aromatase inhibitor resistance? , 2006, The Journal of Steroid Biochemistry and Molecular Biology.
[79] K. Kovács,et al. Suppression of 7,12-Dimethylbenz(α) Anthracene-Induced Breast Carcinoma by Coumarin in the Rat , 1976 .
[80] J. Haesslein,et al. Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: biological activity of RU79115. , 2000, Bioorganic & medicinal chemistry letters.
[81] R. Tekmal,et al. Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. , 1999, Endocrine-related cancer.
[82] R. D. Murray. The naturally occurring coumarins. , 2002, Fortschritte der Chemie organischer Naturstoffe = Progress in the chemistry of organic natural products. Progres dans la chimie des substances organiques naturelles.
[83] C. Dorn,et al. Mirestrol. I. Preparation of the tricyclic intermediate. , 1972, The Journal of organic chemistry.
[84] J. Liehr,et al. Estrogen, DNA damage and mutations. , 1999, Mutation research.
[85] J. Harborne. Progress in the chemistry of organic natural products , 1975 .
[86] M. D. Lloyd,et al. Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent. , 2005, The Biochemical journal.
[87] Angelo Carotti,et al. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. , 2004, Journal of medicinal chemistry.
[88] M. Lang,et al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[89] P. Lønning,et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.
[90] R. Santen,et al. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.
[91] I. Henderson,et al. Cancer of the breast: the past decade (first of two parts). , 1980, The New England journal of medicine.
[92] T. Selmer,et al. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency , 1995, Cell.
[93] K. Korzekwa,et al. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. , 2001, European journal of biochemistry.
[94] N. Harada,et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. , 1999, Cancer research.
[95] R. Coombes,et al. Aromatase inhibitors as adjuvant therapies in patients with breast cancer , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[96] Y. Miyoshi,et al. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[97] J. Dodge,et al. Selective estrogen receptor modulators (SERMs). , 1970, Current pharmaceutical design.
[98] P. Goss,et al. Summary of aromatase inhibitor trials: The past and future , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[99] Hironori Arakawa,et al. Photophysical and (photo)electrochemical properties of a coumarin dye. , 2005, The journal of physical chemistry. B.
[100] A. Lerner,et al. Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells , 1977, Nature.
[101] I. H. Hamelers,et al. 17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor , 2003, Cancer Cell International.
[102] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[103] B. Potter,et al. Steroid sulphatase inhibitors for breast cancer therapy , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[104] R. O’Kennedy,et al. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. , 2004, Current pharmaceutical design.
[105] P. Carrupt,et al. Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies. , 2002, Bioorganic & medicinal chemistry letters.
[106] C. Strott. Sulfonation and molecular action. , 2002, Endocrine reviews.
[107] D. Egan,et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. , 1990, Drug metabolism reviews.
[108] J. V. van Lier,et al. Synthesis and biological activities of nucleoside-estradiol conjugates. , 2006, Bioorganic & medicinal chemistry letters.
[109] A. Howell,et al. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. , 2004, Best practice & research. Clinical endocrinology & metabolism.
[110] D. Hadjipavlou-Litina,et al. Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities. , 2004, Current pharmaceutical design.
[111] M. Dowsett,et al. Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] R. Moffett. CENTRAL NERVOUS SYSTEM DEPRESSANTS. VII. PYRIDYL COUMARINS. , 1964, Journal of medicinal chemistry.
[113] R. Tekmal,et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. , 1996, Cancer research.
[114] D. McDonnell. Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. , 1998, Biochemical Society transactions.
[115] K. Gumireddy,et al. Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. , 2005, Bioorganic & medicinal chemistry.
[116] R. Thornes,et al. The Rarity of Liver Toxicity in Patients Treated with Coumarin (1, 2-Benzopyrone) , 1989, Human toxicology.
[117] D. Muchmore. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. , 2000, The oncologist.
[118] S. Bhagwat,et al. Lead identification of a potent benzopyranone selective estrogen receptor modulator. , 2004, Bioorganic & medicinal chemistry letters.
[119] J. Russo,et al. Genotoxicity of steroidal estrogens , 2004, Trends in Endocrinology & Metabolism.
[120] C. Bond,et al. Structure of a human lysosomal sulfatase. , 1997, Structure.
[121] D. Johnston,et al. Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice. , 1997, Carcinogenesis.
[122] K. Butler,et al. Phase I evaluation of coumarin (1,2-benzopyrone) and cimetidine in patients with advanced malignancies. , 1991, Molecular biotherapy.
[123] S. Kirkiacharian,et al. Synthesis and binding affinity to human α and β estrogen receptors of various 7-hydroxycoumarins substituted at 4- and 3,4- positions , 2004 .
[124] M. Auer,et al. New fluorogenic substrate for the first continuous steroid sulfatase assay. , 2000, Bioorganic & medicinal chemistry letters.
[125] B. Potter,et al. Steroid sulfatase: molecular biology, regulation, and inhibition. , 2005, Endocrine reviews.
[126] L. Wattenberg,et al. Inhibition of Chemical Carcinogen-induced Neoplasia by Coumarins and α-Angelicalactone , 1979 .
[127] J. R. Casley-Smith,et al. Frequency of coumarin hepatotoxicity , 1995, The Medical journal of Australia.
[128] J. Jaén,et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[129] A. Howell,et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.
[130] M. Różalski,et al. Cytotoxic effects, alkylating properties and molecular modelling of coumarin derivatives and their phosphonic analogues. , 2003, European journal of medicinal chemistry.
[131] J. DiGiovanni,et al. Multistage carcinogenesis in mouse skin. , 1992, Pharmacology & therapeutics.
[132] V. Goldmacher,et al. Realizing the full potential of immunotoxins. , 1989, Cancer cells.
[133] S. Akinaga,et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. , 2003, Cancer research.
[134] V. Jordan,et al. Selective estrogen receptor modulation: concept and consequences in cancer. , 2004, Cancer cell.